All In Biotech

Drug Trial Radar · NCT07325136

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Feb 3, 2026

Primary completion

Apr 23, 2029

Study completion Apr 24, 2029

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer

Conditions

  • Relapsed/Refractory Small Cell Lung Cancer

Interventions

  • BMS-986525Drug

    Specified dose on specified days

  • PumitamigDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years
  2. Number of participants with serious adverse events (SAEs)Time frame: Up to approximately 2 years
  3. Number of participants with AEs meeting dose-limiting toxicity (DLT) criteriaTime frame: Up to 21 days
  4. Number of participants with AEs leading to discontinuationTime frame: Up to approximately 2 years
  5. Number of participants with AEs leading to deathTime frame: Up to approximately 2 years

Locations

13 sites in 6 countries. Site status is shown where the registry gives one.

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Local Institution - 0029

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Istituto Clinico Humanitas

    Rozzano, Milano, Italy · Recruiting

  • Local Institution - 0020

    Hirakata, Osaka, Japan · Not yet recruiting

  • Local Institution - 0018

    Chuo-ku, Tokyo, Japan · Not yet recruiting

  • Centrul de Oncologie Sf. Nectarie SRL

    Craiova, Romania · Recruiting

  • Oncohelp Medical Center

    Timișoara, Timiș County, Romania · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.